SAP and Hypertrust Patient Data Care (HPDC), a spin-off of Camelot Consulting Group), created a proof-of-concept implementation for the integrated orchestration of processes using cross-company workflow orchestration. The implementation supports development of advanced and personalized therapies, such as Cell & Gene Therapies (also called Advanced Therapy Medicinal Products, ATMP).
These innovative therapies treat diseases like and rare diseases or cancer, e.g., leukemia. They are tailored to each patient individually as they rely on cell material (blood or tissue) from the patient. The production can only succeed if cooperation partners along the supply chain interact flawlessly – which brings a huge complexity into the underlying supply chain processes with numerous stakeholders. To handle this complexity, it requires new collaboration paradigms within the supply chain.
The underlying Hypertrust X-Chain, an end-to-end supply chain management for Advanced & Personalized Therapies, is based on innovations from Camelot ITLab. With the X-Chain, Hypertrust Patient Data Care already supports biotech and pharma pioneers during the clinical trials of their Cell & Gene Therapies.
Please find more information on the workflow and logistics challenges in Cell & Gene Therapies and how cross-company workflow orchestration helps tackle these in this blog post.
